CLSA released a research report stating that TIGERMED's (03347) Q3 performance reflects a moderate recovery in its business. While margins remain under pressure, the firm expects a potential rebound in product performance by 2026. CLSA largely maintained its revenue forecasts for 2025–2027 but adjusted net profit projections—up 28.9% for 2025 and down 14.6% and 14.1% for 2026 and 2027, respectively—to reflect margin outlook. The target price was revised down from HK$58.9 to HK$52.1, retaining an "Outperform" rating.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.